Malignant Ovarian Clear Cell Tumor
4 clinical trials · Condition
◉ Watch Malignant Ovarian Clear Cell Tumor
| Record | Firm | Date |
|---|---|---|
| Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer (NCT03602586) | National Cancer Institute (NCI) | 2018-12-21 |
| Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent (NCT02470559) | Barbara Ann Karmanos Cancer Institute | 2015-06-01 |
| Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers (NCT02020707) | Mayo Clinic | 2014-02-24 |
| YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy (NCT00899093) | Gynecologic Oncology Group | 2007-09-01 |
Track Malignant Ovarian Clear Cell Tumor automatically
Every clearance here is in the API, with alerts when new ones post.